Response-based treatment of high-risk neuroblastoma
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0002038
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
1. Patients with newly diagnosed high risk neuroblastoma
2. Patients with measurable or evaluable disease
3. Patients with informed consent
Exclusion Criteria
1. Patients with progressive disease or relapse
2. Patients who underwent high dose chemotherapy before
3. Patients with organ dysfunction as follows (creatinine elevation > 3 x upper limit of normal, Total bilirubin > 3 x upper limit of normal, aspartate transaminase/alanine transaminase > 5 x upper limit of normal), ejection fraction <40%)
4. Pregnant or nursing women
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of event free survival
- Secondary Outcome Measures
Name Time Method Rate of late adverse effects